Three years after severe COVID-19 hospitalization, significant risks of mortality and long-term symptoms persist, impacting overall health and quality of life.
Pharma companies delist patents from FDA’s Orange Book following FTC challenges
At least three pharma companies have requested to pull patents from an FDA database after the Federal Trade Commission challenged more than 100 patents it